Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1046	153832-46-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ertapenem invanz ertapenem sodium	Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Molecular weight: 475.52 Formula: C22H25N3O7S CLOGP: -0.83 LIPINSKI: 0 HAC: 10 HDO: 5 TPSA: 156.27 ALOGS: -3.22 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ertapenem
invanz
ertapenem sodium

Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.

Molecular weight: 475.52
Formula: C22H25N3O7S
CLOGP: -0.83
LIPINSKI: 0
HAC: 10
HDO: 5
TPSA: 156.27
ALOGS: -3.22
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	38 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	28.72 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.45 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.80 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-1.941		Moderate	0.79
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.668		Moderate	0.79
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.179	10^-6 cm/s	Moderate	0.79
dh-clint	Dog hepatocyte intrinsic clearance	1.600	uL/min/10^6 cells	Moderate	0.79
dppb	Dog plasma protein binding (% unbound)	52.650	%	Moderate	0.79
fcs-ppb	Fetal calf serum protein binding (% unbound)	54.650	%	Moderate	0.79
herg	hERG pIC50	4.584	pIC50	Moderate	0.79
hh-clint	Human hepatocyte intrinsic clearance	2.259	uL/min/10^6 cells	Moderate	0.79
hlm-clint	Human liver microsomal intrinsic clearance	3.741	uL/min/mg protein	Moderate	0.79
hppb	Human plasma protein binding (% unbound)	31.020	%	Moderate	0.79
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70	36
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC,STK33,TEK	12
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.259		Moderate	0.79
mh-clint	Mouse hepatocyte intrinsic clearance	6.412		Moderate	0.79
mppb	Mouse plasma protein binding (% unbound)	63.740		Moderate	0.79
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.231		Moderate	0.79
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	43.250	%	Moderate	0.79
rh-clint	Rat hepatocyte intrinsic clearance	3.715	uL/min/10^6 cells	Moderate	0.79
rh-fuinc	Rat hepatocyte fraction unbound in incubation	88.930	%	Moderate	0.79
rppb	Rat plasma protein binding (% unbound)	27.920	%	Moderate	0.79
solubility-dd	Solubility at pH 7.4 in DMSO	860.994	uM	Moderate	0.79

Approvals:

Date	Agency	Company	Orphan
April 18, 2002	EMA	Merck Sharp & Dohme Ltd
Nov. 21, 2001	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	1430.53	26.59	406	10427	37564	90580050
Chronic sinusitis	476.62	26.59	157	10676	23645	90593969
Paraesthesia oral	444.01	26.59	160	10673	31499	90586115
Vaginal flatulence	424.77	26.59	124	10709	12514	90605100
Proctitis	401.71	26.59	124	10709	15135	90602479
Female genital tract fistula	390.60	26.59	126	10707	17742	90599872
Radiculopathy	382.22	26.59	125	10708	18380	90599234
Vaginal discharge	372.02	26.59	124	10709	19340	90598274
Procedural pain	355.90	26.59	138	10695	33222	90584392
Oral candidiasis	309.75	26.59	127	10706	35328	90582286
Drug ineffective	255.15	26.59	527	10306	1383771	89233843
Frequent bowel movements	246.28	26.59	125	10708	56810	90560804
Colitis ulcerative	239.56	26.59	125	10708	60141	90557473
Colitis	233.02	26.59	129	10704	69813	90547801
Haematochezia	223.19	26.59	126	10707	70787	90546827
Rectal haemorrhage	205.15	26.59	126	10707	82618	90534996
Therapeutic product effect incomplete	175.12	26.59	161	10672	193735	90423879
Seizure	162.18	26.59	139	10694	152490	90465124
Dyspepsia	136.65	26.59	142	10691	198018	90419596
Hallucination	118.17	26.59	82	10751	65877	90551737
Product use in unapproved indication	116.14	26.59	170	10663	336066	90281548
Erythema	111.44	26.59	137	10696	229109	90388505
Encephalopathy	108.10	26.59	68	10765	46376	90571238
Pyrexia	103.64	26.59	237	10596	660248	89957366
Weight decreased	96.57	26.59	167	10666	379743	90237871
Anaemia	89.53	26.59	155	10678	352647	90264967
Constipation	84.29	26.59	133	10700	280262	90337352
Abdominal pain	69.75	26.59	149	10684	395572	90222042
Epilepsy	69.68	26.59	66	10767	82140	90535474
Disorganised speech	65.50	26.59	19	10814	1866	90615748
Infusion related reaction	62.32	26.59	147	10686	416633	90200981
Clostridium difficile colitis	61.86	26.59	39	10794	26667	90590947
Renal graft infection	54.79	26.59	12	10821	374	90617240
Clostridium difficile infection	53.30	26.59	40	10793	36205	90581409
Malaise	52.14	26.59	171	10662	585815	90031799
Confusional state	51.08	26.59	130	10703	386075	90231539
Status epilepticus	49.92	26.59	30	10803	18844	90598770
Clostridium test positive	49.33	26.59	20	10813	5381	90612233
Fatigue	48.87	26.59	40	10793	1153983	89463631
Mitochondrial toxicity	48.33	26.59	12	10821	651	90616963
Mental status changes	47.97	26.59	41	10792	44638	90572976
Arthralgia	45.75	26.59	18	10815	778504	89839110
Avian influenza	45.27	26.59	8	10825	78	90617536
Off label use	44.51	26.59	253	10580	1101999	89515615
Skin odour abnormal	44.42	26.59	14	10819	1821	90615793
Generalised tonic-clonic seizure	43.66	26.59	35	10798	34868	90582746
Raoultella ornithinolytica infection	43.60	26.59	8	10825	98	90617516
Hallucination, visual	39.66	26.59	28	10805	23064	90594550
Neurotoxicity	39.14	26.59	27	10806	21440	90596174
Wound secretion	37.24	26.59	16	10817	4974	90612640
Band neutrophil count decreased	35.90	26.59	7	10826	121	90617493
Drug reaction with eosinophilia and systemic symptoms	35.58	26.59	34	10799	42724	90574890
Abdominal discomfort	35.49	26.59	7	10826	477321	90140293
Nasopharyngitis	34.76	26.59	4	10829	407100	90210514
Acute generalised exanthematous pustulosis	34.23	26.59	21	10812	13682	90603932
Delirium	33.36	26.59	51	10782	104308	90513306
Pathogen resistance	32.66	26.59	17	10816	8098	90609516
Alopecia	31.51	26.59	10	10823	495061	90122553
Bone marrow eosinophilic leukocyte count increased	30.88	26.59	5	10828	27	90617587
Allergic hepatitis	29.53	26.59	5	10828	37	90617577
Hypersensitivity	29.26	26.59	9	10824	454668	90162946
Pain in extremity	28.85	26.59	9	10824	450520	90167094
Toxic encephalopathy	28.79	26.59	16	10817	8683	90608931
Synovitis	28.75	26.59	3	10830	329749	90287865
Tooth discolouration	28.41	26.59	9	10824	1189	90616425
Weight increased	27.38	26.59	8	10825	417919	90199695
Seizure like phenomena	27.10	26.59	9	10824	1381	90616233

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Confusional state	285.87	24.04	229	6797	167368	42446941
Product use in unapproved indication	236.42	24.04	214	6812	184242	42430067
Seizure	227.29	24.04	175	6851	120386	42493923
Hallucination	179.78	24.04	114	6912	57393	42556916
Epilepsy	170.16	24.04	84	6942	26087	42588222
Pathogen resistance	160.15	24.04	63	6963	11387	42602922
Encephalopathy	154.80	24.04	92	6934	41241	42573068
Toxic encephalopathy	117.78	24.04	44	6982	6909	42607400
Delirium	115.94	24.04	84	6942	52435	42561874
Hallucination, visual	111.94	24.04	59	6967	20961	42593348
Myoclonus	108.55	24.04	54	6972	17011	42597298
Clostridium difficile colitis	108.51	24.04	58	6968	21194	42593115
Disorganised speech	78.09	24.04	22	7004	1406	42612903
Drug resistance	73.75	24.04	54	6972	34194	42580115
Generalised tonic-clonic seizure	71.75	24.04	48	6978	26331	42587978
Status epilepticus	67.05	24.04	38	6988	15540	42598769
Neurotoxicity	66.65	24.04	44	6982	23607	42590702
Clostridium test positive	62.19	24.04	26	7000	5479	42608830
Disorientation	49.78	24.04	44	6982	36345	42577964
Malacoplakia	49.46	24.04	14	7012	910	42613399
Agitation	47.95	24.04	56	6970	64258	42550051
Drug reaction with eosinophilia and systemic symptoms	46.19	24.04	45	6981	42030	42572279
Biliary sepsis	40.56	24.04	12	7014	912	42613397
Dysarthria	38.95	24.04	40	6986	39767	42574542
Serotonin syndrome	38.88	24.04	33	6993	25812	42588497
Drug interaction	38.86	24.04	114	6912	266885	42347424
Urinary tract inflammation	34.26	24.04	8	7018	240	42614069
Neuromyopathy	34.02	24.04	11	7015	1123	42613186
Mental disorder	33.40	24.04	26	7000	18003	42596306
Conductive deafness	33.03	24.04	9	7017	508	42613801
Myasthenia gravis crisis	32.87	24.04	10	7016	836	42613473
Pseudomonal sepsis	31.68	24.04	15	7011	4234	42610075
Neutropenia	29.78	24.04	86	6940	199345	42414964
Eosinophilic pneumonia acute	28.96	24.04	9	7017	808	42613501
Rash morbilliform	28.95	24.04	14	7012	4139	42610170
Eosinophilia	28.51	24.04	31	6995	32868	42581441
Appendicitis perforated	27.37	24.04	11	7015	2095	42612214
Mental status changes	27.01	24.04	34	6992	42081	42572228
Eosinophilic pneumonia	26.83	24.04	14	7012	4860	42609449
Arterial angioplasty	26.57	24.04	5	7021	50	42614259
Vitamin B1 deficiency	25.42	24.04	7	7019	411	42613898
Anticonvulsant drug level decreased	25.38	24.04	9	7017	1216	42613093
Foot amputation	24.44	24.04	8	7018	849	42613460
Incorrect product administration duration	24.37	24.04	14	7012	5866	42608443

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	459.36	22.32	158	16466	21501	110551174
Chronic sinusitis	425.47	22.32	155	16469	24929	110547746
Vaginal flatulence	397.14	22.32	123	16501	12021	110560654
Paraesthesia oral	391.44	22.32	158	16466	33513	110539162
Female genital tract fistula	367.78	22.32	125	16499	16394	110556281
Proctitis	357.01	22.32	123	16501	16804	110555871
Vaginal discharge	350.22	22.32	123	16501	17785	110554890
Radiculopathy	344.76	22.32	124	16500	19212	110553463
Seizure	317.85	22.32	264	16360	220921	110351754
Procedural pain	309.99	22.32	136	16488	35429	110537246
Product use in unapproved indication	308.75	22.32	357	16267	447020	110125655
Hallucination	292.87	22.32	185	16439	101247	110471428
Oral candidiasis	262.14	22.32	130	16494	44630	110528045
Confusional state	261.48	22.32	336	16288	468344	110104331
Encephalopathy	252.01	22.32	155	16469	80900	110491775
Epilepsy	205.77	22.32	148	16476	100061	110472614
Frequent bowel movements	190.56	22.32	124	16500	71266	110501409
Colitis ulcerative	176.76	22.32	122	16502	77241	110495434
Pathogen resistance	171.69	22.32	73	16551	17599	110555076
Clostridium difficile colitis	168.12	22.32	96	16528	43682	110528993
Colitis	165.39	22.32	131	16493	102192	110470483
Haematochezia	157.58	22.32	134	16490	115390	110457285
Hallucination, visual	141.83	22.32	83	16541	39522	110533153
Disorganised speech	136.10	22.32	40	16584	3263	110569412
Delirium	135.82	22.32	132	16492	134893	110437782
Rectal haemorrhage	133.57	22.32	124	16500	119709	110452966
Therapeutic product effect incomplete	123.63	22.32	160	16464	223645	110349030
Myoclonus	117.74	22.32	69	16555	32929	110539746
Dyspepsia	117.34	22.32	144	16480	190821	110381854
Toxic encephalopathy	115.95	22.32	53	16571	15161	110557514
Clostridium test positive	112.48	22.32	47	16577	10846	110561829
Status epilepticus	109.97	22.32	65	16559	31506	110541169
Generalised tonic-clonic seizure	108.14	22.32	79	16545	54601	110518074
Neurotoxicity	104.53	22.32	70	16554	42137	110530538
Pyrexia	98.37	22.32	327	16297	897938	109674737
Drug resistance	88.51	22.32	71	16553	56303	110516372
Clostridium difficile infection	78.34	22.32	64	16560	52065	110520610
Drug reaction with eosinophilia and systemic symptoms	78.29	22.32	78	16546	82017	110490658
Fatigue	73.89	22.32	46	16578	1215912	109356763
Erythema	73.87	22.32	146	16478	291301	110281374
Mental status changes	70.15	22.32	71	16553	76051	110496624
Drug ineffective	60.34	22.32	412	16212	1520128	109052547
Anaemia	59.50	22.32	199	16425	546887	110025788
Arthralgia	58.67	22.32	22	16602	779610	109793065
Infusion related reaction	56.84	22.32	155	16469	381007	110191668
Weight decreased	55.15	22.32	175	16449	467882	110104793
Joint swelling	51.44	22.32	4	16620	442841	110129834
Disorientation	51.14	22.32	58	16566	70613	110502062
Malacoplakia	50.87	22.32	15	16609	1237	110571438
Constipation	46.03	22.32	138	16486	357648	110215027
Renal graft infection	43.68	22.32	12	16612	767	110571908
Off label use	42.42	22.32	376	16248	1499809	109072866
Eosinophilic pneumonia	42.29	22.32	21	16603	7206	110565469
Agitation	41.98	22.32	67	16557	112984	110459691
Avian influenza	40.71	22.32	8	16616	113	110572562
Pain in extremity	39.63	22.32	12	16612	487106	110085569
Granulomatous dermatitis	38.48	22.32	10	16614	516	110572159
Conductive deafness	38.48	22.32	9	16615	299	110572376
Nasopharyngitis	37.41	22.32	7	16617	394354	110178321
Raoultella ornithinolytica infection	37.32	22.32	8	16616	177	110572498
Abdominal pain	37.09	22.32	164	16460	512825	110059850
Weight increased	36.65	22.32	9	16615	419635	110153040
Metabolic encephalopathy	36.49	22.32	22	16602	11038	110561637
Dyspnoea	34.35	22.32	72	16552	1106800	109465875
Band neutrophil count decreased	34.30	22.32	7	16617	121	110572554
Skin odour abnormal	33.68	22.32	13	16611	2441	110570234
Alopecia	33.49	22.32	7	16617	364746	110207929
Endotracheal intubation	33.45	22.32	17	16607	6127	110566548
Acute generalised exanthematous pustulosis	31.29	22.32	26	16598	21638	110551037
Eosinophilia	31.26	22.32	41	16583	57895	110514780
Urinary tract inflammation	31.23	22.32	8	16616	390	110572285
Neutropenia	31.13	22.32	125	16499	374495	110198180
Eosinophilic pneumonia acute	30.87	22.32	11	16613	1654	110571021
Synovitis	30.39	22.32	3	16621	274089	110298586
Neuromyopathy	30.16	22.32	11	16613	1768	110570907
Vomiting	30.15	22.32	57	16567	910618	109662057
Biliary sepsis	29.78	22.32	11	16613	1832	110570843
Abdominal discomfort	29.76	22.32	11	16613	393847	110178828
Bone marrow eosinophilic leukocyte count increased	29.58	22.32	5	16619	28	110572647
Cross sensitivity reaction	29.14	22.32	15	16609	5552	110567123
Tooth discolouration	29.09	22.32	10	16614	1353	110571322
Escherichia test positive	28.93	22.32	13	16611	3571	110569104
Wound secretion	28.82	22.32	16	16608	6885	110565790
General physical health deterioration	28.74	22.32	14	16610	425281	110147394
Dysarthria	28.71	22.32	48	16576	84073	110488602
Vitamin B1 deficiency	28.25	22.32	9	16615	961	110571714
Stomatitis	27.39	22.32	4	16620	270238	110302437
Allergic hepatitis	27.13	22.32	5	16619	49	110572626
Arterial angioplasty	27.03	22.32	5	16619	50	110572625
Mitochondrial toxicity	26.93	22.32	12	16612	3233	110569442
Seizure like phenomena	26.78	22.32	11	16613	2430	110570245
Myasthenia gravis crisis	26.30	22.32	10	16614	1804	110570871
Peripheral swelling	26.26	22.32	14	16610	404020	110168655
Lower respiratory tract infection	26.08	22.32	3	16621	243103	110329572
Erythema multiforme	25.75	22.32	23	16601	21074	110551601
Anxiety	25.46	22.32	10	16614	345068	110227607
Product preparation issue	25.40	22.32	11	16613	2768	110569907
Back pain	25.39	22.32	12	16612	370984	110201691
Unresponsive to stimuli	25.33	22.32	39	16585	63751	110508924
Malaise	25.21	22.32	180	16444	671639	109901036
Hypoaesthesia	25.08	22.32	8	16616	314215	110258460
Anticonvulsant drug level decreased	24.71	22.32	10	16614	2126	110570549
Swelling	24.57	22.32	11	16613	351030	110221645
Urinary tract infection pseudomonal	24.33	22.32	10	16614	2212	110570463
Rash morbilliform	24.15	22.32	15	16609	7936	110564739
Mental disorder	23.37	22.32	29	16595	38762	110533913
Foot amputation	23.00	22.32	8	16616	1120	110571555
Hallucinations, mixed	22.92	22.32	15	16609	8678	110563997
Abdominal pain upper	22.82	22.32	12	16612	349099	110223576
Wound	22.57	22.32	4	16620	234433	110338242
Contusion	22.42	22.32	4	16620	233357	110339318

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DH03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
FDA CS	M0024174	Carbapenems
FDA EPC	N0000175496	Penem Antibacterial
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
CHEBI has role	CHEBI:36047	antibacterial drug

Related Drugs by ATC class:

J01DH Carbapenems 10 drugs

betamipron biapenem cilastatin doripenem imipenem meropenem panipenem relebactam tebipenem pivoxil vaborbactam

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute bacterial peritonitis	indication	31860008
Bacterial pneumonia	indication	53084003	DOID:874
Miscarriage with sepsis	indication	67465009
Haemophilus influenzae pneumonia	indication	70036007
Abdominal abscess	indication	75100008
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Community acquired pneumonia	indication	385093006
Peptostreptococcus infection	indication	135341000119101
Urinary tract infection caused by Klebsiella	indication	369001000119100
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection	indication
Septic Abortion due to Porphyromonas	indication
Post-Op Gynecologic Infection due to Porphyromonas	indication
Klebsiella Pyelonephritis	indication
Post-Op Gynecological Peptostreptococcus Infection	indication
Complicated E. Coli Peritonitis	indication
Postpartum Endomyometritis due to E. Coli	indication
Colorectal Surgery Infection Prevention	indication
Diabetic Foot Infection	indication
Streptococcal Septic Abortion	indication
Postpartum Endomyometritis due to Peptostreptococcus	indication
Post-Op Gynecologic Infection due to Bacteroides	indication
Postpartum Endomyometritis due to Bacteroides	indication
E. Coli Septic Abortion	indication
E. Coli Pyelonephritis	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Complicated Skin and Skin Structure E. Coli Infection	indication
Peptostreptococcus Septic Abortion	indication
Complicated Bacterial Peritonitis	indication
Complicated Bacteroides Peritonitis	indication
Moraxella Catarrhalis Pneumonia	indication
Post-Op Gynecologic Infection due to Prevotella	indication
Bacteroides Septic Abortion	indication
Post-Op Gynecological Infection due to E. Coli	indication
Postpartum Endomyometritis due to Porphyromonas	indication
Postpartum Endomyometritis due to Streptococcus	indication
Postpartum Endomyometritis due to Prevotella	indication
Post-Op Gynecologic Infection, due to Streptococcus	indication
Prevotella Septic Abortion	indication
Complicated Skin and Skin Structure Infection	indication
Gas gangrene caused by clostridium perfringens	off-label use	266093005
Clostridium Perfringens Empyema	off-label use
Acute nephropathy	contraindication	58574008
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Lesion of brain	contraindication	301766008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.79	acidic
pKa2	4.1	acidic
pKa3	6.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Bioact source	MoA source
D-alanyl-D-alanine carboxypeptidase DacB	Enzyme	DACB_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF		WOMBAT-PK
Penicillin-binding protein 2	Enzyme	Q9X6V3_PSEAI		WOMBAT-PK
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6	Enzyme	Q7CHG0_YERPE		WOMBAT-PK
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU		WOMBAT-PK
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5	Enzyme	Q9X6V7_PSEAI		WOMBAT-PK

External reference:

ID	Source
4021283	VUID
N0000148720	NUI
D04049	KEGG_DRUG
153773-82-1	SECONDARY_CAS_RN
4021283	VANDF
C1120106	UMLSCUI
CHEBI:404903	CHEBI
6H7	PDB_CHEM_ID
CHEMBL1359	ChEMBL_ID
CHEMBL1232	ChEMBL_ID
D000077727	MESH_DESCRIPTOR_UI
DB00303	DRUGBANK_ID
10906	IUPHAR_LIGAND_ID
8049	INN_ID
G32F6EID2H	UNII
150610	PUBCHEM_CID
325642	RXNORM
16218	MMSL
173352	MMSL
274067	MMSL
42474	MMSL
d04783	MMSL
009554	NDDF
009555	NDDF
385573008	SNOMEDCT_US
385574002	SNOMEDCT_US
396346003	SNOMEDCT_US
G32F6EID2H	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3843	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3843	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3845	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3845	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
ertapenem sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9398	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9429	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3510	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	16714-889	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	25021-199	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	32 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	25021-199	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	32 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	43598-901	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44567-820	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44647-051	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	51810-504	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6196	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	63323-823	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	68001-408	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	Human Prescription Drug Label	1	68083-351	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	72266-159	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	25 sections

Ask DrugCentral

Try a sample question

ertapenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: